Company / FCF Margin
BioMarin Pharmaceutical FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
22.5%
FY2025
5-year range
2.6% / 22.5%
FY2021-FY2025
Trend
+31.8%
vs FY2024
Sector context
#23 of 134
Health Care
What the data says
BioMarin Pharmaceutical's fcf margin of 22.5% is higher than 83% of companies in the Health Care sector (FY2025). Improved from 2.6% to 22.5% over the past 2 years.
Based on SEC 10-K filings.
22.5% in FY2025 with a 5-year CAGR of +24.1%. Top quartile in the Health Care sector.
Improved from 2.6% to 22.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +19.9pp
- 5-Year Change
- +24.1pp
- 10-Year Change
- -
Sector benchmark
Top 17% in Health CareTop 17% of 134This company 22.5% Sector average -637.8%
▼
+103.5% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 31.8% year-over-year.
- Currently 660.3pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 22.5% | +31.8% |
| FY2024 | 17.1% | +559.5% |
| FY2023 | 2.6% | -1.1% |
| FY2022 | 2.6% | -76.9% |
| FY2021 | 11.3% | +825.6% |
| FY2020 | -1.6% | +72.5% |
| FY2019 | -5.7% | +31.9% |
| FY2018 | -8.3% | +47.3% |
| FY2017 | -15.8% | +53.0% |
| FY2016 | -33.7% | +33.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026